A ranar 31 ga Maris, 2026, Cibiyar Kimanta Magunguna ta Hukumar Kayayyakin Lafiya ta Ƙasa ta China ta bayar da labarai masu daɗi: An haɗa GFH375, wanda GenFleet Therapeutics ta ƙirƙiro, a hukumance a matsayin wanda zai yi maganin marasa lafiya da ke fama da cutar kansar pancreas da ta kama da maye gurbin KRAS G12D waɗanda suka sami aƙalla magani ɗaya a baya. Wannan yana nuna muhimmin mataki a fannin maganin cutar kansar pancreas.
Idan kai ko ƙaunatacce yana fama da cutar kansar pancreas mai saurin kamuwa da cutar KRAS G12D, kada ka yanke ƙauna. Sashen Duniya na Asibitin Oncology na Yankin Kudu na Beijing (400-880-3716) yana bin diddigin wannan ci gaba na zamani kuma yana ba da shawarwari da ayyukan daidaitawa na ƙwararru ga marasa lafiya na ƙasashen waje.
**Game da GFH375/VS-7375**
GFH375 wani ƙaramin ƙwayar halitta ne mai aiki da baki, mai ƙarfi, kuma mai zaɓe sosai wanda aka ƙera don kai hari ga musayar GTP/GDP, ta haka yana kawo cikas ga kunna hanyar da ke ƙasa da kuma hana yaduwar ƙwayoyin ƙari yadda ya kamata. Nazarin asibiti ya nuna hanawa dangane da kashi a cikin samfuran da ke ɗauke da maye gurbin KRAS G12D; GFH375 ya kuma nuna ƙarancin haɗarin da ba a kai hari ba a cikin zaɓin kinase da gwaje-gwajen manufa ta aminci.
GenFleet ta shiga cikin haɗin gwiwar ganowa da haɓaka tare da Verastem Oncology (Nasdaq: VSTM) don haɓaka sabbin shirye-shiryen cutar kansa guda uku waɗanda ke niyya ga cututtukan daji da ke haifar da hanyar RAS/MAPK. Haɗin gwiwar ya ba Verastem zaɓi na musamman don samun lasisi ga kowane ɗayan mahaɗan uku bayan kammala nasarar matakan da aka riga aka tsara a cikin gwajin Mataki na I. A watan Disamba na 2023, Verastem ya zaɓi GFH375/VS-7375, wani maganin hana KRAS G12D (ON/OFF) na baki, a matsayin babban shirinta daga haɗin gwiwar, kuma lasisin GFH375 da aka yi amfani da shi a watan Janairun 2025 shine na farko daga wannan haɗin gwiwa. Lasisin ya ba Verastem haƙƙoƙin haɓaka da kasuwanci a wajen China, yayin da GenFleet ke riƙe haƙƙoƙi a cikin China.
**Bayanan gwajin asibiti na Mataki na I/II masu kyau da aka gabatar a Majalisar ESMO ta 2025:**
- Kashi 91.5% na marasa lafiya sun sami raguwar raunukan da aka yi niyya
- Matsakaicin amsawar manufa (ORR) ya kai kashi 40.7%
- Adadin rage cututtuka (DCR) ya kai kashi 96.7%
- Matsakaicin rayuwa ba tare da ci gaba ba (mPFS) ya kasance watanni 5.52
- Adadin tsira daga ci gaba na watanni 4 ya kai kashi 78.2%
Waɗannan bayanai, waɗanda aka samo daga marasa lafiya 59 da ke fama da ciwon daji na hanji mai tsanani (KRAS G12D-mutant pancreatic ductal adenocarcinoma (PDAC) waɗanda aka yi musu magani a baya, sun nuna ƙarfin aikin GFH375 na hana ciwon daji a cikin ciwon daji na pancreas.
**Me Yasa Zabi Sashen Kasa da Kasa na Asibitin Oncology na Yankin Kudu na Beijing?**
A matsayinta na jagora a ayyukan kiwon lafiya na duniya, Sashen Kasa da Kasa na Asibitin Oncology na Yankin Kudu na Beijing ya kuduri aniyar samar wa marasa lafiya na duniya da:
- Shawarwari kan lafiya na ƙwararru da kuma ayyukan ganawa da malamai da dama.
- Samun damar samun manyan kwararru kan cutar kansa a China da kuma na duniya baki daya
- Tashar kore mai tsayawa ɗaya don maganin likita na ƙetare iyaka
Mun fahimci cewa ga marasa lafiya da ke fama da cutar kansa, kowace rana ta jira tana kawo ƙarin haɗari. Saboda haka, mun kafa hanyoyin tuntuɓar juna na ƙasashen duniya da yawa masu dacewa don tabbatar da cewa kun sami tallafin ƙwararru akan lokaci.
**Tuntube mu a yau kuma ku fara tafiyarku ta bege**
��� Layin Sadarwa: 400-880-3716
��� WeChat: 17801183037
��� Imel:
- 100085_010@163.com
- myimmnet@163.com
Ko da kuwa wace ƙasa ko yanki kake ciki, ko kuma yawan hanyoyin magani da ka riga ka gwada, Sashen Ƙasa da Ƙasa na Asibitin Oncology na Yankin Kudu na Beijing a shirye yake ya tsaya tare da kai a yaƙin da kake yi da cutar kansa. Ci gaban GFH375 na iya zama hasken da kake jira.
Call 400-880-3716, add us on WeChat at 17801183037, or email us at 100085_010@163.com or myimmnet@163.com.
Tare, bari mu yi ƙoƙari don ƙarin damar rayuwa.
> Lura: Har yanzu ba a amince da GFH375 a hukumance don tallatawa a babban yankin China ba. Ana sa ran sanya shi a matsayin maganin gaggawa zai hanzarta samun damar asibiti. Sashen Kasa da Kasa na Asibitin Oncology na Yankin Kudu na Beijing zai sa ido sosai kan ci gaban da ake samu a fannin samun magunguna da kuma samar da bayanai kan magunguna na zamani da ayyukan daidaitawa ga marasa lafiya da suka cancanta. Da fatan za a bi jagorar likitan ku game da takamaiman tsare-tsaren magani.
Lokacin Saƙo: Afrilu-10-2026